Highlights Cellectis S.A.

Equities

ALCLS

FR0010425595

Market Closed - Euronext Paris Other stock markets 11:35:24 2024-04-30 am EDT			After market 12:33:15 pm
2.435 ^EUR	-0.61%		2.443	+0.33%

Apr. 29	Cellectis S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Apr. 29	Cellectis S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cellectis S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 29	CI
Cellectis S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Apr. 29	CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4%	Apr. 26	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	Apr. 25	MT
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs	Apr. 22	CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down	Apr. 19	MT
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading	Apr. 16	MT
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	Apr. 15	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	Apr. 09	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading	Apr. 03	MT
European Equities Traded in the US as American Depositary Receipts Start Week Modestly Higher	Apr. 01	MT
AstraZeneca: $300 million invested in the USA	Feb. 06	CF
Cellectis: second tranche of EIB loan drawn down	Jan. 17	CF
France's Cellectis Signs $140 Million Equity Investment Deal with AstraZeneca	Nov. 15	MT
AstraZeneca to Buy Stake in Cellectis, Enter Research Accord on Cell Therapy; Cellectis Shares More Than Double	Nov. 01	MT
AstraZeneca launches collaboration and investment deal with Cellectis	Nov. 01	AN
AstraZeneca, Cellectis Team Up to Develop Cell, Gene Therapy Products	Nov. 01	MT
Astrazeneca Announces Collaboration and Investment Agreement with Cellectis to Accelerate Development of Next Generation Therapeutics in Areas of High Unmet Need, Including Oncology, Immunology and Rare Diseases	Nov. 01	CI
Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of A Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase ? Syndrome Type 1	23-10-12	CI
Earnings Flash (ALCLS) CELLECTIS Reports Q2 Revenue $2.7M	23-08-07	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Cellectis S.A.

Equities

ALCLS

FR0010425595

Highlights

Filters